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The aim of this prospective, multicenter Phase IIa study
was to investigate whether daily intravenous busulfan (IV
Bu) with bortezomib is a safe and effective conditioning
regimen prior to second, salvage autologous hematopoietic
stem cell transplantation (ASCT) for relapsed multiple
myeloma (MM) patients.
Thirty patients with relapsed MM were enrolled at 11
centers in the US and Canada. Median age at second ASCTwas
59years (range:48-73).Median time fromﬁrstASCT to second
ASCT was 28.0 months (range: 12-119). At the time of second
ASCT, 7 (23.3%) patients were in very good partial response
(VGPR), 12 (40.0%) in partial response (PR), 2 (6.7%) in stable
disease (SD), and 9 (30.0%) in progressive disease (PD).
Patients received a test IV Bu dose (0.8mg/kg) over 2 hours
between Days -12 and -9. The test PK dosing was based on
adjusted ideal body weight (AIBW¼ ideal BW + 0.25 [actual
BWe ideal BW]) for all patients except for thosewhose actual
BW is less than or equal to the ideal BW. For those subjects,
actual BW was used. Pharmacokinetic (PK) analysis deter-
mined Bu exposure as area under the concentration-time
curve (AUC), and provided optimized doses so that a total
target AUC would achieve 20,000 mMmin. These optimized
doseswere administered over 3 hours, once daily fromDay -5
toDay -2. Conﬁrmatory PKwas conducted onDay -5; Bu doses
were furtheradjustedonDays -3and-2, if needed.Bortezomib
(1.3 mg/m2) was intravenously administered on Day -1.
The most common grade 3 or 4 adverse events (CTCAE
v3.0) were febrile neutropenia (50.0%), stomatitis (43.3%),
and nausea (13.3%). One transplant-related death occurred
due to pulmonary complications in a patient with Parkin-
son's disease on Day 20. There were no reported instances of
seizure, worsening neuropathy, or hepatic veno-occlusive
disease meeting the Baltimore criteria.
Post-transplant disease response using the 2006 IMWG
criteriawas available for 28 patients. At 3months, therewere
2 (6.7%) CR, 5 (16.7%) VGPR, 4 (13.3%) PR, 8 (26.7%) SD, and 9
(30.0%) PD. At 6 months, there was 1 (3.3%) stringent CR, 1
(3.3%) CR, 4 (13.3%) VGPR, 7 (23.3%) SD, and 14 (46.7%) PD.
Median progression-free survival was 191 days, while
median overall survival was not reached.
Test PK showed that 40.0% (n¼12/30) of patients had AUC
<1,000 (n¼11) and AUC >1,500 mM*min (n¼1). If body
weight-based doses had been used without test PK, these
patients (40%) would have been dosed outside the target
total AUC range (>24,000 or < 16, 000 mM*min) for condi-
tioning. The conﬁrmatory PK on Day -5 revealed that a total
AUC fell within the target range in 28 patients (93.3%), while
two (6.7%) needed dose reduction on Days -3 and -2.
In conclusion, a combination of IV Bu and bortezomib prior
to second ASCT had acceptable safety proﬁle and induced
20% VGPR or better responses at 6 months. No cases of VOD
were observed in this group of patients in whom dose opti-
mization using pre-transplant test PK was utilized.147
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Delayed engraftment following high-dose chemotherapy
and autologous peripheral stem cell transplantation is a rare
event. Here, we report two cases of delayed engraftment
following autologous peripheral blood stem cell transplant
(PBSCT) for Multiple Myeloma (MM) associated with early
recovery of polyclonal lymphocytes and response to steroids.
Bothof our patientswere 51years oldat timeof transplant and
women. The preparative regimen consisted of Melphalan
200mg/m2 prior to stem cell infusion; the stem cell doses
were between 2.5 and 2.8 million per kilogram. Per protocol,
each received growth factor beginning at day 5 post-trans-
plant. Both patients demonstrated a relative increase in their
peripheral blood lymphocyte count without neutrophil
recoverybyday15 inonepatientandday25post-transplant in
theother. Peripheralblood forﬂowcytometrywasnegative for
lymphoproliferative disorder or recurrence of their disease.
However, it was noted that their CD4:CD8 ratio was 1:6.5 and
1:6.3 with marked increase in CD8 lymphoctyes. This expan-
sion of CD8+ cells has been implicated in autoimmune cyto-
penias inpatientswith autoimmunediseases andwas thought
to be the cause of cytopenias in our patients. Given thedelay in
neutrophil recovery, prednisone 1mg/kg was started for
concerns that thepredominantlyCD8polyclonal lymphocytes
were responsible for suppressing hematopoiesis. Within 48-
72 hours of starting steroids, the peripheral blood lympho-
cytes decreased signiﬁcantly, and both patients demonstrated
neutrophil engraftment followed by platelet engraftment in
the subsequent two-week period. Delayed engraftment
following autologous PBSCT is uncommon. Viral infection is
a common etiology, and rarely, lymphoproliferative processes
like large granular lymphocytes (LGL) have been reportedpost
high-dose therapy and autologous PBSCT for MM. In our
patients, no viral cause was found and there was no clonal
lymphocyte population. In conclusion, this is theﬁrst report of
post autologous PBSCT delayed engraftment in association
with apredominantlyCD8polyclonal lymphocytepopulation.
Thisprocesswas readily reversiblewith corticosteroid therapy
and did not necessitate re-transplantation.148
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Background: A recent study showed that ASCT may reverse
kidney failure in one third of multiple myeloma patients,
which can lead to improvement in blood pressure. However,
there is very limited published data studying the impact of
the treatment on blood pressure control.
Methods: We conducted a review of electronic medical
records of 184 patients with established diagnosis of MM
that underwent an ASCT at Karmanos Cancer Institute
between January 1st, 2009 and December 31st, 2010. We
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weeks before the transplant and then at days 0, 30,100 and
180. Other data includes GFRwhich is calculated by using the
Cockcroft Gault formula at the same intervals, sub-type of
MM and Durie-Salmon stage at diagnosis, disease response
to therapy, BMI at baseline; and other comorbidities such as
diabetes, hyperlipedemia and coronary artery disease.
Statistical analyses were performed using the statistical
package of SPSS version 18. All P-values were 2-sided.
Results: In this study 184 patients were included. The sample
demographics at baseline arepresented inTable 1. Association
between BP stages and disease status before ASCT and at day
0was statistically signiﬁcant (p¼.025 , X2¼14.408); therewas
no statistically signiﬁcant association between stages of HTN
at 0 , 30,100 and180daysafter theASCT in regards to age , race
or gender. Mean Systolic and diastolic BP-value showed no
statistically signiﬁcant difference at the same intervals
respectively. In addition, there was no correlation between
stages of HTN, and stages or type ofMM. The only statistically
signiﬁcant association between chronic kidney disease (CKD)
stages and BP stages was at day 0 (day ASCT infused) (P¼.032,
X2 ¼26.670. The association between CKD stages and diseaseTable 1
Demographic characteristics of the simple
Patient Characteristics Number (%)
Gender
Male 100 (54%)
Median age years (range) 59 (33-73)
Race
White 138 (75%)
African-American 41 (22%)
Other 5 (3%)
Marital status
Never married 18 (10%)
Now married 127 (69%)
Separated 13 (7%)
Widowed 6 (3%)
Divorced 20 (11%)
Health insurance
Medicare 180 (98%)
Other 4 (2%)
BMI
Normal 42 (23%)
Overweight 64 (35%)
Obese 42 (23%)
Severely obese 36 (19%)
BP stage
Normal 32 (17%)
Prehypertension 78 (43%)
Stage 1 HTN 64 (35%)
Stage 2 HTN 19 (5%)
CKD stage
1 60 (33%)
2 82 (45%)
3A 24 (13%)
3B 10 (5%)
4 5 (3%)
5 3 (1%)
Myebma stage
IA 17 (19%)
IIA 25 (14%)
IIIA 130 (71%)
IIIB 12 (6%)
Disease status
VGPR 65 (35%)
PR 57 (31%)
CR 26 (14%)
SD 18 (10%)
PD 16 (9%)
SCR 2 (1%)
Melphalan dose
200 mg 140 (76%)
140 mg 44 (24%)status at 100 days aftermelphalanwas statistically signiﬁcant
(P¼.043, X2¼25.568). The associations betweenBP stages and
BMI stages were borderline or statistically signiﬁcant at 30
days (P¼.054 and X2¼16.665), 100 days (P¼.026 and
X2¼18.947) and 180 days(P¼.001, X2¼27.120).
Conclusion: There was no direct effect of ASCT on blood
pressure improvement. Other factors such as BMI and
disease status at baseline appear to play more roles on Bp
control. Majority of our patient were transplanted at early
stages of (CKD) which can explain the result. We suggest
a prospective study that evaluates the impact of ASCT in MM
patients with high BP.
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No standard method for HSC mobilization prior to autolo-
gous stem cell transplant (ASCT) exists. We performed
a retrospective analysis on consecutive adult patients (pts)
undergoing mobilization for ASCT between 1/2009 and 1/
2012 to compare efﬁcacy of mobilization method and trans-
plant outcome.Method ofmobilizationwas per the discretion
of the attending physician. Chemotherapy andG-CSF (Chemo/
G)were used if therapyor cytoreductionwas necessary for the
underlying malignancy. Per institutional guideline cytokine
onlymobilizationusedG-CSF (G)10ug/kgdailywithapheresis
startingonday5andplerixafor (G/P)0.24mg/kgwasaddedon
day 4 if the peripheral bloodCD34+ cells/ulwas< 15. A total of
343 pts underwent 362 attempts at collection, 192 with G/P,
135 with G alone, and 35 after chemo/G. The median days of
apheresis for all three groups was 2 (range 1-4) and the
number of cumulative CD 34 cells collected after mobilization
was5.7(0-19), 6.8 (1.9-20.9), and6.3(0-19)million/kg in theG/
P, G, and chemo/G groups, respectively (p¼NS). Failure to
mobilize CD34 cells was deﬁned as never reaching 10 or
greater peripheral blood CD34+ cells/ul or collecting less than
2millionCD34+ cells/kg. Per institutional guideline 192 of 327
collections (59%) starting with G-CSF alone required the
addition of plerixafor. Nine of 192 collections (4.6%) in the G/P
group failed tomobilize and 2were rescuedwith a secondG/P
mobilization. Twelve of 35 collections (34%) in the chemo/G
group failed to mobilize and 8 were subsequently mobilized
adequately with G/P. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells. Engraftment and day 100
transplant outcomes were not different between the groups.
In conclusion, themethodofmobilizingHSC for ASCTdoes not
seem to affect clinical outcome, pts that fail mobilization after
chemo/G for treatment of active disease or cytoreduction can
be remobilizedwithG/P, andour current institutionalprotocol
to beginmobilizationwithG alone and add plerixafor on day 4
as described above allows a high rate of mobilization success.
Further prospective studies are needed to assess pharmacoe-
conomic and quality of life issues related to HSC mobilization.
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